Page 3 - Operating Subsidiary News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Operating subsidiary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Operating Subsidiary Today - Breaking & Trending Today

Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nephrology at Johns Hopkins University School of Medicine

Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its wholly-owned operating subsidiary, My Health Logic Inc. ("My Health Logic"), has received a letter of support on the Company's chronic kidney disease (CKD) technology from nephrologist Chirag R. Parikh, MD, PhD Director, Division of Nephrology at Johns Hopkins University School of Medicine. This letter supports the Company's belief that its lab-on-chip device for the early detection of CKD has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD. ....

United States , Drug Administration , Johns Hopkins University School Of Medicine , Division Of Nephrology , My Health Logic , Health Logic Interactive , Company Management Discussion , Health Logic Interactive Inc , Company Article Featured In Stat News , Venture Exchange , Ronald Peterson Professor , Johns Hopkins University School , Article Featured , Stat News , Logic Interactive , Health Logic , United States Food , The Company , Dr Parikh , Chronic Kidney Disease , Health Logic Interactive Inc , Chiragr Parikh , Operating Subsidiary , Logic Interactive , ஒன்றுபட்டது மாநிலங்களில் , ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து ,

Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029

Press release content from Business Wire. The AP news staff was not involved in its creation.
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029
February 10, 2021 GMT
SOMERSET, N.J. (BUSINESS WIRE) Feb 10, 2021
Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $550 million in aggregate principal amount of 3.125% senior unsecured notes due 2029 (the “Notes”) at par, which represents an increase of $75 million from the offering size previously announced. ....

United States , New Jersey , Paul Surdez , Catalent Pharma Solutions Inc , Catalent Inc , European Union , Securities Exchange , Catalent Pharma Solutions , Operating Subsidiary , Private Offering , Securities Act , Securities Exchange Act , Annual Report , Business Wire , Products And Services , Coronavirus Pandemic , Consumer Products And Services , Intellectual Property , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic , Infectious Diseases , Corporate News , North America , Diseases And Conditions ,

Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029

Press release content from Business Wire. The AP news staff was not involved in its creation.
Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029
February 10, 2021 GMT
SOMERSET, N.J. (BUSINESS WIRE) Feb 10, 2021
Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $475 million in aggregate principal amount of senior unsecured notes due 2029 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). ....

United States , New Jersey , Paul Surdez , Catalent Pharma Solutions Inc , Catalent Inc , European Union , Securities Exchange , Catalent Pharma Solutions , Securities Act , Operating Subsidiary , Private Offering , Securities Exchange Act , Annual Report , Business Wire , Products And Services , Coronavirus Pandemic , Consumer Products And Services , Intellectual Property , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic , Infectious Diseases , Corporate News , North America , Diseases And Conditions ,